在指甲骨综合征非编码基因组:遗传诊断作为个性化后续指南
Perrine Brunelle1, Anne-Sophie Jourdain1, Fabienne Escande1
1Univ. Lille, CHU Lille, ULR7364 RADEME, FHU G4 Génomique, F-59000, Lille, France.
European journal of human genetics : EJHG
|March 3, 2026
概括
在LMX1B基因中发生的非编码DNA变异会导致指甲纹状综合征 (NPS),这是一种罕见的遗传性疾病. 了解这些调节异常对于准确的基因诊断和个性化医疗方法至关重要.
科学领域:
- 遗传学 遗传学 是一个
- 发展生物学 发展生物学
- 人类疾病 人类疾病
背景情况:
- 甲状腺综合征 (NPS) 是一种罕见的遗传疾病,影响骨发育,功能和眼睛健康.
- NPS的发病与LMX1B基因功能障碍有关,这是一个对肢体,脏和眼睛发育至关重要的转录因子.
- 肢体中的LMX1B表达是由称为LMX1B自我调节模块 (LARMs) 的特定肢体增强剂调节的.
研究的目的:
- 研究非编码基因组在NPS中的作用.
- 在NPS.家族中识别和描述LMX1B位点的调节异常.
- 了解非编码变体如何对NPS变异性和遗传模式产生影响.
主要方法:
- 对受影响家庭的LMX1B监管环境的分析.
- 识别遗传变异,包括CRE删除,影响CRE促进体相互作用的结构变异和5'UTR变异.
- 确定非编码变化的分子特征及其对LMX1B表达的影响.
主要成果:
- 四个家族在LMX1B位点呈现出明显的调控异常.
- 确定的变异包括CRE删除,两个破坏CRE促进器相互作用的结构变异,以及导致上游开放阅读框架 (ORF) 的5'UTR变异.
- 这些非编码性改变解释了不归因于编码区域突变的NPS病例,突出了组织特异性影响和修改后的遗传.
结论:
- 非编码基因组变化是NPS的重要贡献者,解释了大约5%的病例.
- 这些调节异常可能导致NPS的可变表达性和改变的遗传模式.
- 包括LMX1B编码和非编码区域在内的基因组诊断对于精准医学和NPS中的遗传咨询至关重要.
更多相关视频
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
相关概念视频
Incomplete Dominance
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
